Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLT-015 PK and Safety in Schizophrenia
NCT05516121Phase 1Completed
- Sponsor
- CF Pharma
- Start
- Feb 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VLT-015 in schizophrenia, sponsored by CF Pharma. Primary endpoints: Maximum plasma concentration at 3 weeks, Time to maximum concentration at 3 weeks and 5 more. Started Feb 2021; status: completed.
02
Drugs
VLT-015
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05516121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516121.